GlassScriptPhysician profile
Jennifer Shinkle
NPI 1760052534
$716.88
in general payments reported to CMS, 2019-2025
17 companies · $168 in 2025
The $168 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $88.63 · 2022: $332 · 2023: $116 · 2024: $13.15 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $296.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $139.60 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $113.67 | 2025 | Rexulti |
| Amgen INC. | $78.97 | 2021-2024 | Prolia, Evenity, Otezla |
| Novo Nordisk INC | $58.07 | 2022-2023 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $53.40 | 2022-2023 | Trelegy Ellipta |
| Abbvie INC. | $51.66 | 2022-2023 | |
| Biohaven Pharmaceuticals, INC. | $40.75 | 2021 | |
| Lilly USA, LLC | $32.26 | 2022-2025 | Mounjaro, Zepbound |
| Alkermes, INC. | $18.63 | 2021 | |
| Sanofi-Aventis U.S. LLC | $18.49 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.25 | 2025 | Caplyta |
| Ultragenyx Pharmaceutical INC. | $17.52 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $17.34 | 2025 | Airsupra |
| Novartis Pharmaceuticals Corporation | $17.16 | 2022 | |
| Xeris Pharmaceuticals, INC. | $14.85 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $13.65 | 2023 | Renasys Touch, Renasys Go V2 Home |
| Baxter Healthcare | $12.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Shinkle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.